These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 24598841

  • 21. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD.
    Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
    [Abstract] [Full Text] [Related]

  • 22. [Study of abnormal iron metabolism parameters and iron overload in patients with myelodysplastic syndromes].
    Song LL, Zheng QQ, Xiao C, Guo J, Wu D, Su JY, Zhou LY, Chang CK.
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct 14; 37(10):903-907. PubMed ID: 27801326
    [Abstract] [Full Text] [Related]

  • 23. Hepcidin levels and their determinants in different types of myelodysplastic syndromes.
    Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, Cortelezzi A, Corbella M, Bosi A, Reda G, Olivieri O, Cappellini MD.
    PLoS One; 2011 Oct 14; 6(8):e23109. PubMed ID: 21886780
    [Abstract] [Full Text] [Related]

  • 24. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
    Musto P, Modoni S, Alicino G, Savino A, Longo A, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G.
    Haematologica; 1994 Oct 14; 79(6):493-9. PubMed ID: 7896207
    [Abstract] [Full Text] [Related]

  • 25. The association between growth differentiation factor-15, erythroferrone, and iron status in thalassemic patients.
    Youssry I, Samy RM, AbdelMohsen M, Salama NM.
    Pediatr Res; 2024 Mar 14; 95(4):1095-1100. PubMed ID: 37464096
    [Abstract] [Full Text] [Related]

  • 26. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I.
    Tamary H, Shalev H, Perez-Avraham G, Zoldan M, Levi I, Swinkels DW, Tanno T, Miller JL.
    Blood; 2008 Dec 15; 112(13):5241-4. PubMed ID: 18824595
    [Abstract] [Full Text] [Related]

  • 27. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
    de Montalembert M, Ribeil JA, Brousse V, Guerci-Bresler A, Stamatoullas A, Vannier JP, Dumesnil C, Lahary A, Touati M, Bouabdallah K, Cavazzana M, Chauzit E, Baptiste A, Lefebvre T, Puy H, Elie C, Karim Z, Ernst O, Rose C.
    PLoS One; 2017 Dec 15; 12(3):e0172147. PubMed ID: 28257476
    [Abstract] [Full Text] [Related]

  • 28. Erythropoiesis and Iron Parameters in Transfusion-dependent and Nontransfusion-dependent Thalassemias.
    Ozturk Z, Gumuslu S, Yalcin K, Kupesiz A.
    J Pediatr Hematol Oncol; 2021 Jul 01; 43(5):186-192. PubMed ID: 34157011
    [Abstract] [Full Text] [Related]

  • 29. What regulates hepcidin in poly-transfused β-Thalassemia Major: erythroid drive or store drive?
    Chauhan R, Sharma S, Chandra J.
    Indian J Pathol Microbiol; 2014 Jul 01; 57(1):39-42. PubMed ID: 24739829
    [Abstract] [Full Text] [Related]

  • 30. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin.
    Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL.
    Nat Med; 2007 Sep 01; 13(9):1096-101. PubMed ID: 17721544
    [Abstract] [Full Text] [Related]

  • 31. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.
    Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M.
    Sci Transl Med; 2019 Jul 10; 11(500):. PubMed ID: 31292266
    [Abstract] [Full Text] [Related]

  • 32. Characterization of iron metabolism and erythropoiesis in erythrocyte membrane defects and thalassemia traits.
    Sulovska L, Holub D, Zidova Z, Divoka M, Hajduch M, Mihal V, Vrbkova J, Horvathova M, Pospisilova D.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Jun 10; 160(2):231-7. PubMed ID: 26592557
    [Abstract] [Full Text] [Related]

  • 33. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E, Kantarjian HM, Koller C, Taher A.
    Cancer; 2008 Mar 01; 112(5):1089-95. PubMed ID: 18186499
    [Abstract] [Full Text] [Related]

  • 34. The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome.
    Metzgeroth G, Rosée PL, Kuhn C, Schultheis B, Dorn-Beineke A, Hehlmann R, Hastka J.
    Eur J Haematol; 2007 Jul 01; 79(1):8-16. PubMed ID: 17532764
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation.
    Barcellini W, Zaninoni A, Gregorini AI, Soverini G, Duca L, Fattizzo B, Giannotta JA, Pedrotti P, Vercellati C, Marcello AP, Fermo E, Bianchi P, Cappellini MD.
    Br J Haematol; 2019 May 01; 185(3):523-531. PubMed ID: 30828802
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Effect of GDF15 on iron overloading and erythropoiesis].
    Zhao YS, Chang CK.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr 01; 19(2):537-41. PubMed ID: 21518525
    [Abstract] [Full Text] [Related]

  • 39. Iron overload in myelodysplastic syndromes (MDS).
    Gattermann N.
    Int J Hematol; 2018 Jan 01; 107(1):55-63. PubMed ID: 29177643
    [Abstract] [Full Text] [Related]

  • 40. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II.
    Casanovas G, Swinkels DW, Altamura S, Schwarz K, Laarakkers CM, Gross HJ, Wiesneth M, Heimpel H, Muckenthaler MU.
    J Mol Med (Berl); 2011 Aug 01; 89(8):811-6. PubMed ID: 21475976
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.